Rekrutierung

Stand: 1. September 2010, eingeschlossene Patienten 8637

Adalimumab (Humira®)	1815
Abatacept (Orencia®)	245
Anakinra (Kineret®)	89
Certolizumab (Cimzia®)	68
Etanercept (Enbrel®)	1642
Golimumab (Simponi®)	48
Infliximab (Remicade®)	702
Rituximab (MabThera®)	1039
Tocilizumab (RoACTEMRA®)	293
Kontrollen	2696

Publikationen

Artikel

Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5. Epub 2010 Jan 8. 

A. Strangfeld, L. Gäwert, A. Bussmann, A. Gräßler, E. Wilden, J. Listing, A. Zink. Therapie mit Biologika bei älteren Patienten mit rheumatoider Arthritis – Ergebnisse aus dem deutschen Biologika-Register RABBIT. Treatment with biologics in Older Patients with Rheumatoid Arthritis – Results from the German Biologics Register Rabbit. Akt Rheumatol 2009; 34: 291– 298. 

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of Herpes Zoster in patients with rheumatoid arthritis treated with anti-TNFalpha agents. JAMA 2009; 301 (7): 737-744.

Anja Strangfeld, Franka Hierse, Jörn Kekow, Ulrich von Hinueber, Hans-Peter Tony, Rainer Dockhorn, Joachim Listing and Angela Zink. Comparative effectiveness of TNFalpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009 68: 1856-1862, http://ard.bmj.com/cgi/reprint/68/12/1856 originally published online January 6, 2009; doi:10.1136/ard.2008.098467.

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A. Does Tumor Necrosis Factor α Inhibition Promote or Prevent Heart Failure in Patients With Rheumatoid Arthritis? Arthritis Rheum. 2008 March;58(3):667-677.

Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M , Wassenberg S, Kapelle A , Listing J. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006 Nov;54(11):3399-407.

Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther, 2006. Published Online first 5 Apr 2006; http://arthritis-research.com/content/8/3/R66 Arthritis Res Ther. 2006;8(3):R66.

Listing J, Strangfeld, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005 Nov;52(11):3403-12.

Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R. Treatment Continuation in Patients Receiving Biological Agents or Conventional DMARD Therapy. Ann Rheum Dis. 2005 Sep; 64(9):1274-1279. Published Online first 11 February 2005.

Abstracts

Increased risk of sepsis after termination of anti-TNFα treatment.
EULAR, Rom, 16.-19. Juni 2010

Does the risk of serious infections in anti-TNF treated patients decrease over time?
American College of Rheumatology, 73. National Meeting, Philadelphia, 17.-21. Oktober 2009

Effectiveness of treatment with Rituximab depends on autoantibody status - results from 2 years of experience in the German biologics register RABBIT.
American College of Rheumatology, 73. National Meeting, Philadelphia, 17.-21. Oktober 2009

Infektionen unter Biologika - Wie hoch ist das Risiko?
37. Kongress der Deutschen Gesellschaft für Rheumatologie, Köln, 23.-26. September 2009

Biologic treatment in elderly patients: specific safety concerns.
EULAR, Kopenhagen, 10.-13. Juni 2009

Leflunomide increases the risk for incident peripheral neuropathies in patients with RA.
American College of Rheumatology, 72. National Meeting, San Francisco, 24.-29. Oktober 2008

Pregnancy Outcome after Exposure to Biologics: Results from the German Biologics Register RABBIT.
American College of Rheumatology, 71. National Meeting, Boston, 06.-11. November 2007

Reaktivierungen latenter Herpesinfektionen bei RA-Patienten unter anti-TNF Therapie - Daten aus dem RABBIT-Register.
35. Kongress der Deutschen Gesellschaft für Rheumatologie, Hamburg, 19.-22. September 2007

Reactivation of herpesviruses (HHV-1 and HHV-3) infections is increased in RA patients treated with adalimumab or infliximab.
EULAR,Barcelona,13.-16.Juni 2007

A highly active disease, treatment with glucocorticoids or coxibs but not the treatment with tnf inhibitors were identified as risk factors for a cardiac failure in RA.
American College of Rheumatology, 70. National Meeting, Washington DC, 10.- 15. November 2006

Patients who are ineligible for clinical trials have lower treatment response in daily practice than those who fulfil standard inclusion criteria.
American College of Rheumatology, 70. National Meeting, Washington DC, 10.- 15. November 2006

Erhöhen Biologika das Risiko einer Herzinsuffizienz bei RA-Patienten?
34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21. Oktober 2006

Sicherheit und Verträglichkeit der Biologikatherapie - Neues aus dem RABBIT-Register.
34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21. Oktober 2006

Patients treated with biologics in daily practice differ in treatment response according to their eligibility for the major RCTs.
EULAR, Amsterdam, 21.-24. Juni 2006

Poster 

Effectiveness of treatment with rituximab depends on autoantibody status - results from 2 years of experience in the German biologics register RABBIT.
American College of Rheumatology, 73. National Meeting, Philadelphia, 17.-21. Oktober 2009

Behandlung von RA-Patienten mit Abatacept - Daten aus dem RABBIT-Register.
37. Kongress der Deutschen Gesellschaft für Rheumatologie, Köln, 23.-26. September 2009

Hohe Inzidenz von Pankreaskarzinomen bei RA-Patienten.
37. Kongress der Deutschen Gesellschaft für Rheumatologie, Köln, 23.-26. September 2009

Increased incidence of pancreatic carcinoma in rheumatoid arthritis patients receiving leflunomide.
EULAR, Kopenhagen, 10.-13. Juni 2009

RA patients treated with Rituximab – routine care data of the German biologics register RABBIT.
American College of Rheumatology, 72. National Meeting, San Francisco, 24.-29. Oktober 2008

No increased risk of solid tumours in patients treated with biologics.
American College of Rheumatology, 72. National Meeting, San Francisco, 24.-29. Oktober 2008

Behandlung von Patienten mit Rheumatoider Arthritis mit Rituximab - Daten aus dem RABBIT-Register.
36. Kongress der Deutschen Gesellschaft für Rheumatologie, Berlin, 24.-27. September 2008

Kein erhöhtes Risiko maligner Tumore unter Biologika.
36. Kongress der Deutschen Gesellschaft für Rheumatologie, Berlin, 24.-27. September 2008

Leflunomid erhöht das Risiko für das Auftreten einer peripheren Neuropathie bei Patienten mit RA.
36. Kongress der Deutschen Gesellschaft für Rheumatologie, Berlin, 24.-27. September 2008

No increased risk of solid tumours in patients treated with biologics – a nested case-control study from the German biologics register RABBIT.
EULAR,Paris,11.-14. Juni 2008

RA patients with prior malignancy under treatment with biologics.
EULAR,Paris,11.-14. Juni 2008

Leflunomide is an acceptable combination partner for TNF inhibitors if methotrexate is not tolerated – results from the German biologics register.
American College of Rheumatology, 71. National Meeting, Boston, 06.-11. November 2007

Schwangerschaften bei RA-Patientinnen unter einer Therapie mit Biologika - Daten aus dem RABBIT-Register.
35. Kongress der Deutschen Gesellschaft für Rheumatologie, Hamburg, 19.-22. September 2007

Relapse rates during the first year after withdrawal of anti-TNF treatment because of remission.
EULAR,Barcelona,13.-16.Juni 2007

Long-term continuation of anti-TNF treatment in combination with either methotrexate or leflunomide compared to monotherapy - results from the German biologics register.
EULAR,Barcelona,13.-16.Juni 2007

Time to relapse in RA patients withdrawn from anti-tnf treatment because of remission.
American College of Rheumatology, 70. National Meeting, Washington DC, 10.- 15. November 2006

Wie lange hält bei RA Patienten eine Remission nach dem Absetzen von Adalimumab, Etanercept oder Infliximab noch an?
34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21. Oktober 2006

Durchführung des Tuberkulose-Screenings vor Beginn einer Biologika-Therapie – Wie genau werden die Empfehlungen hierzu befolgt?
34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21. Oktober 2006

Biologics increase the chance of remission by two. Results from the German biologics register.
EULAR, Amsterdam, 21.-24. Juni 2006

Significantly higher chance of 'functional remission' or physical independence in RA patients receiving biologics. Results from the German biologics register.
EULAR, Amsterdam, 21.-24. Juni 2006

Adherence to published guidelines on TB screening before the start of treatment with biologics in Germany.
EULAR, Amsterdam, 21.-24. Juni 2006

Infections in RA patients treated with infliximab or etancercept.
Eular, Wien, 8. - 11. Juni 2005

No relevant escalation in dosage of infliximab or other biologic agents over 12 months of treatment - Results from the German Biologic Register.
American College of Rheumatology, 68. National Meeting, San Antonio, 16. - 21. Oktober 2004

Long Term Observation of Biologics in Germany - Which Patients Are Treated with Biologic Compounds?
EULAR, Berlin, 9. - 12. Juni 2004

Long Term Observation of Biologics in Germany - Safety Data after 6 Months.
EULAR, Berlin, 9. - 12. Juni 2004

Langzeitbeobachtung der Behandlung der rheumatoiden Arthritis mit Biologika - Unerwünschte Ereignisse im ersten Therapiehalbjahr.
32. Kongress der Deutschen Gesellschaft für Rheumatologie, Frankfurt, 3. - 6. September 2003

Langzeitbeobachtung der Behandlung der rheumatoiden Arthritis mit Biologika in Deutschland: Behandlungsanamnese und aktuelle Therapie.
32. Kongress der Deutschen Gesellschaft für Rheumatologie, Frankfurt, 3. - 6. September 2003

Newsletter